An ADC comprising anti-SLC44A4 antibody conjugated to MMAE by a VC linker (ASG-5ME) controlled tumor growth in multiple tumor models, including subcutaneous and orthotopic PDX models of pancreatic cancer [58]. Here, SLC44A4 is linked to neoplasm.